Understanding Your Tirzepatide Dosing Chart

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published June 12, 2025 • Updated May 3, 2026

Most patients do not ask for a tirzepatide dosing chart because they love pharmacology. They ask because they want to know what happens next. How long am I on 2.5 mg? When do I move to 5 mg? If I stop losing, do I go up? If I feel sick, do I push through? And the question underneath all of that is usually: am I doing this right?

The honest answer is that tirzepatide dosing should be clinician-managed. A chart can show the labeled path, but it cannot tell you whether your nausea is manageable, whether your constipation is becoming unsafe, whether your protein intake is too low, whether your plateau is normal, or whether your dose increase would help or hurt. That is why I treat the chart as a map, not a command.

At Gaya Wellness, I use tirzepatide inside a broader medical weight loss framework. The medication can be powerful, but it is not the whole protocol. The protocol includes diagnosis, labs, contraindication screening, nutrition, muscle preservation, menopause context, and follow-up.

The Tirzepatide Dosing Chart Most Patients See

For chronic weight management, FDA-approved tirzepatide is marketed as Zepbound. The labeled starting dose is 2.5 mg injected under the skin once weekly for 4 weeks. After that, the dose may increase to 5 mg once weekly. If additional treatment effect is needed and the dose is tolerated, the label allows further 2.5 mg increases after at least 4 weeks on the current dose.

The commonly discussed maintenance doses are 5 mg, 10 mg, or 15 mg once weekly. The 2.5 mg dose is for treatment initiation; it is not intended as the long-term maintenance target. That does not mean every patient must climb quickly. It means the start is deliberately low so the body has time to adapt before the medication reaches stronger therapeutic levels.

That table is intentionally simple. It is not a personalized prescription. If you are using tirzepatide, your dose should come from your prescriber, your response, your tolerance, and your goals. If you are using a compounded product, the conversation becomes even more important because milligrams, concentration, units, and syringe markings can be confused.

Why 2.5 mg Is the Starting Dose

The 2.5 mg start is not a test of your willpower. It is a tolerability step. Tirzepatide affects appetite, gastric emptying, and incretin signaling. If the dose is pushed too aggressively, patients can develop nausea, vomiting, reflux, diarrhea, constipation, dehydration, low intake, fatigue, and food aversion. Those problems can derail treatment before it has a chance to work.

This is why I do not treat the first month as a failure if the scale does not move dramatically. Some women lose weight right away. Others notice food noise drop before the scale follows. Others need the first month simply to learn how their body responds. Early treatment is about safety, education, and stability.

In the SURMOUNT-1 trial published in the New England Journal of Medicine, adults with obesity or overweight without diabetes received tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks with lifestyle intervention. Tirzepatide produced substantial average weight loss compared with placebo, but that result came from structured dosing, trial monitoring, and time. It was not a 4-week sprint.

That distinction matters for women over 40, where perimenopause, menopause, sleep disruption, insulin resistance, alcohol tolerance, stress load, and muscle loss can all change the weight-loss curve. A dose chart does not see those variables. A clinician should.

Escalation Is Not Automatic

The label gives a framework for escalation, but a framework is not an obligation. Before increasing tirzepatide, I want to know what happened on the current dose. Is the patient losing weight at a reasonable rate? Is appetite controlled enough to follow a plan? Is constipation mild or escalating? Is nausea limiting protein? Is hydration adequate? Are there abdominal symptoms that need evaluation?

I also ask whether the current dose is already doing the job. Some patients respond well at lower doses. If a woman is losing steadily, eating enough protein, lifting, sleeping better, and tolerating the medication, I do not increase just because a calendar says the next box is available. More medication is not automatically better medicine.

The opposite is also true. Some patients need dose escalation because the lower dose is not enough. That can be appropriate. The problem is dose chasing: increasing every time the scale slows without asking why. A plateau can happen because the body is adapting, because constipation is masking fat loss, because protein is too low, because strength training is missing, because the patient is eating too little during the week and rebounding on weekends, or because hormones and sleep are driving appetite.

Inside Weight Loss Concierge, this is where the visit matters. We are not just asking what the number on the scale did. We are asking whether the plan is preserving muscle, whether symptoms suggest hormonal imbalance, whether stubborn weight gain reflects insulin resistance, and whether the medication strategy still fits the person in front of us.

Side Effects Should Guide the Dosing Conversation

The most common dose-limiting issues are gastrointestinal. Nausea, constipation, reflux, diarrhea, vomiting, early fullness, and low appetite are not just inconveniences. They can affect hydration, electrolyte balance, protein intake, bowel function, kidney strain, and the ability to maintain lean mass.

Before moving from one dose to the next, I want side effects stable. Mild nausea that resolves with meal changes may be manageable. Severe vomiting is different. Occasional constipation is different from no bowel movement for several days with pain and bloating. A little appetite reduction is different from not being able to eat enough protein to protect muscle.

The FDA has also raised concerns about unapproved GLP-1 products, including dosing errors and adverse events. That is clinically relevant because many patients are handed instructions in units instead of milligrams, with little understanding of concentration. If a dose chart from the internet does not match the product in your hand, do not improvise.

Side effects are also why I care about slower titration when needed. Some patients need to stay on a dose longer before escalating. Some need a dose pause. Some need nutrition changes, constipation treatment, hydration strategy, or a different medication. The goal is not to prove you can tolerate misery. The goal is effective treatment that your body can actually sustain.

What a Plateau Really Means

A plateau does not automatically mean tirzepatide stopped working. Weight loss is rarely linear. Early loss can include water and glycogen changes. Later loss often slows as the body becomes smaller, energy needs decrease, and appetite patterns adapt. That is physiology, not failure.

When a patient plateaus, I review the basics before changing the dose. Are injections being taken on schedule? Has alcohol crept back in? Is constipation affecting the scale? Is protein high enough? Is the patient doing resistance training or only walking? Has sleep worsened? Are hot flashes, night sweats, mood changes, or joint pain reducing movement? Are medications such as steroids, some antidepressants, or some sleep aids affecting weight?

For women in midlife, plateau conversations often overlap with hormone therapy evaluation, metabolic health, and muscle preservation. If the body is losing muscle, the scale may look successful at first and then stall in a way that becomes harder to recover from. This is why I want weight loss paired with protein targets and strength work, not just dose escalation.

Sometimes a higher tirzepatide dose is the right next step. Sometimes it is not. If the current dose is causing poor intake, increasing can make the plateau worse by making the patient weaker, more constipated, and less consistent. If the current dose is tolerated and food noise has returned, escalation may be reasonable. The answer depends on the whole clinical picture.

Do Not Build Your Plan Around Someone Else’s Chart

Online dosing charts can be useful for education, but they become dangerous when patients compare themselves to strangers. Your friend may tolerate 10 mg beautifully. You may need more time at 5 mg. Another patient may lose well at 7.5 mg and never need 15 mg. Someone else may need to stop because side effects or contraindications change the risk-benefit balance.

There are also medication-specific details. Tirzepatide should not be combined with another tirzepatide-containing product or another GLP-1 receptor agonist unless a clinician is specifically managing the transition. Patients with diabetes medications may need blood sugar monitoring and medication adjustment. Women who can become pregnant need contraception and pregnancy planning conversations. Patients preparing for surgery or anesthesia should tell their surgical team they use a GLP-1 or dual-incretin medication.

That is why a real plan starts before the first injection. At Gaya, we look at body weight, waist pattern, blood pressure, A1c, lipids, kidney and liver context, thyroid history, gallbladder history, medication list, pregnancy status when relevant, and whether the patient’s symptoms point toward Hormonal Agency, Weight Loss Concierge, or a different starting point.

How Gaya Manages Tirzepatide Dosing

My approach is simple: start with the label, then personalize based on the patient. The chart tells us the guardrails. The patient tells us the plan. If a woman is tolerating the medication, losing weight appropriately, eating enough protein, and protecting muscle, we may continue. If she is miserable, under-eating, constipated, or weak, we slow down and fix the plan before chasing a stronger dose.

Weight Loss Concierge is built for that kind of decision-making. It is physician-led medical weight loss for women who need more than a prescription. The program can include GLP-1 strategy, lab review, side-effect support, hormone-aware planning, protein targets, strength guidance, and maintenance thinking from the beginning.

Some women need Foundation, which is GLP-1 Access at $149/mo. Some need Premium, which is GLP-1 Included at $349/mo. Some need Concierge, which combines GLP-1 plus HRT at $549/mo. If weight, hot flashes, sleep, belly fat, cravings, and fatigue are all present, the answer is rarely just “increase the dose.” The answer is a metabolic plan that can see the whole woman.

If you are already on tirzepatide and confused by your dosing chart, bring the exact product name, dose, concentration if compounded, injection instructions, start date, side effects, weight trend, protein intake, and medication list to your clinician. The safest dose is not the highest dose. It is the dose that gives meaningful benefit with tolerable risk, good nutrition, preserved strength, and a plan for what happens next.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in medical weight loss, hormone optimization, and longevity medicine for women in midlife and beyond.

You have not failed. Your plan did.